Renalytix AI (GB:RENX) has released an update.
Renalytix AI, an AI-enabled diagnostics company specializing in kidney disease, reports that its Non-Executive Chairman, Christopher Mills, has engaged in significant stock transactions. Mills sold and subsequently bought back a substantial number of ordinary shares, resulting in a net holding of 14,609,946 shares, or 7.7% of the company. This movement reflects confidence and material interest in the company’s future by a key insider.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
